Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, Mark S. Freedman et al.|The Lancet Neurology|2013Cited by 233
Oral fingolimod (FTY720) in multiple sclerosisPaul O’Connor, Ludwig Kappos, Giancarlo Comi et al.|Neurology|2009Cited by 191
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsCristoforo Comi, Paul O’Connor, Xavier Montalbán et al.|Multiple Sclerosis Journal|2009Cited by 158